Research programme: erythropoietin receptor agonists - Viking TherapeuticsAlternative Names: EPO receptor agonists - Viking Therapeutics; LG 5640
Latest Information Update: 06 Feb 2015
At a glance
- Originator Neurogen Corporation
- Developer Viking Therapeutics
- Class Small molecules
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Anaemia